Submit Content
Get the latest delivered to your inbox
Privacy Policy

Introducing Biogen's 2021 Diversity, Equity & Inclusion Report

Published 11-04-21

Submitted by Biogen

Biogen DEI Report cover 2021

Diversity makes us stronger and helps drive innovation. We’re proud of the progress we’ve made in advancing our diversity, equity, and inclusion commitments. We also know that we have much more to do, and we are in it for the long haul.

Learn more in our 2021 Diversity, Equity & Inclusion report

Biogen Logo

Biogen

Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain. We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

More from Biogen

Join today and get the latest delivered to your inbox